Goldman Sachs Group Inc Dia Medica Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 121,802 shares of DMAC stock, worth $509,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121,802
Previous 121,802
-0.0%
Holding current value
$509,132
Previous $461,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding DMAC
# of Institutions
62Shares Held
6.06MCall Options Held
14.9KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.35MShares$5.65 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$2.53 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX600KShares$2.51 Million5.72% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$2.33 Million0.0% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.6 Million0.5% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $111M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...